A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1, first-in-human, open-label study of JAB-8263 to determine the maximum
tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT. 30 subjects with
advanced solid tumor will be enrolled.